Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Birth Outcomes and Successive Pregnancy Rates in Adolescents Attending a Specialised Antenatal Clinic.

Tung JS, Kwek LK, Nadarajah S, Sulaiman S.

Ann Acad Med Singapore. 2018 Jan;47(1):44-47. No abstract available.

2.

Antenatal corticosteroids administration: are we giving them at the right time?

Wong TTC, Tung JSZ, Lau HCQ, Tagore S.

Arch Gynecol Obstet. 2018 Feb;297(2):373-379. doi: 10.1007/s00404-017-4577-4. Epub 2017 Oct 29.

PMID:
29082422
3.

Timing of antenatal steroids exposure and its effects on neonates.

Lau HCQ, Tung JSZ, Wong TTC, Tan PL, Tagore S.

Arch Gynecol Obstet. 2017 Dec;296(6):1091-1096. doi: 10.1007/s00404-017-4543-1. Epub 2017 Sep 25.

PMID:
28948354
4.

Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions.

Lariosa-Willingham KD, Rosler ES, Tung JS, Dugas JC, Collins TL, Leonoudakis D.

BMC Res Notes. 2016 Sep 5;9(1):444. doi: 10.1186/s13104-016-2219-8.

5.

A high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cells.

Lariosa-Willingham KD, Rosler ES, Tung JS, Dugas JC, Collins TL, Leonoudakis D.

BMC Res Notes. 2016 Sep 5;9(1):419. doi: 10.1186/s13104-016-2220-2.

6.

Development of a central nervous system axonal myelination assay for high throughput screening.

Lariosa-Willingham KD, Rosler ES, Tung JS, Dugas JC, Collins TL, Leonoudakis D.

BMC Neurosci. 2016 Apr 22;17:16. doi: 10.1186/s12868-016-0250-2.

7.

Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitors.

Ng RA, Sun M, Bowers S, Hom RK, Probst GD, John V, Fang LY, Maillard M, Gailunas A, Brogley L, Neitz RJ, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, Adler M, Yao N, Zmolek W, Nakamura D, Quinn KP, Sauer JM, Bova MP, Ruslim L, Artis DR, Yednock TA.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4674-9. doi: 10.1016/j.bmcl.2013.06.006. Epub 2013 Jun 11.

PMID:
23856050
8.

Low-lying spinal cord and tethered cord syndrome in children with anorectal malformations.

Teo AT, Gan BK, Tung JS, Low Y, Seow WT.

Singapore Med J. 2012 Sep;53(9):570-6.

9.

School-located immunization programs: do parental preferences predict behavior?

Middleman AB, Tung JS.

Vaccine. 2011 Apr 27;29(19):3513-6. doi: 10.1016/j.vaccine.2011.02.101. Epub 2011 Mar 15.

PMID:
21414378
10.

Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.

Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Sham HL, Jagodzinski J, Toth G, Brecht E, Yao N, Pan H, Lin M, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Gauby S, Zmolek W, Quinn KP, Sauer JM.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6034-9. doi: 10.1016/j.bmcl.2010.08.070. Epub 2010 Aug 19.

PMID:
20822903
11.

Urban middle school parent perspectives: the vaccines they are willing to have their children receive using school-based immunization programs.

Middleman AB, Tung JS.

J Adolesc Health. 2010 Sep;47(3):249-53. doi: 10.1016/j.jadohealth.2010.01.009. Epub 2010 Apr 2.

PMID:
20708563
12.

Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents.

Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, Tóth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4789-94. doi: 10.1016/j.bmcl.2010.06.112. Epub 2010 Jun 25.

PMID:
20634069
13.

At what sites are parents willing to have their 11 through 14-year-old adolescents immunized?

Middleman AB, Tung JS.

Vaccine. 2010 Mar 19;28(14):2674-8. doi: 10.1016/j.vaccine.2010.01.006. Epub 2010 Jan 17.

PMID:
20085835
14.

Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.

Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DW, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Dappen MS, Toth G, Pan H, Ruslim L, Miller J, Bova MP, Sinha S, Quinn KP, Sauer JM.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6386-91. doi: 10.1016/j.bmcl.2009.09.061. Epub 2009 Sep 19.

PMID:
19811916
15.

Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists.

Dressen D, Garofalo AW, Hawkinson J, Hom D, Jagodzinski J, Marugg JL, Neitzel ML, Pleiss MA, Szoke B, Tung JS, Wone DW, Wu J, Zhang H.

J Med Chem. 2007 Oct 18;50(21):5161-7. Epub 2007 Sep 19.

PMID:
17880055
16.

Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase.

Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS, Walker DE, Davis D, Thorsett ED, Jewett NE, Moon JB, John V.

J Med Chem. 2004 Jan 1;47(1):158-64.

PMID:
14695829
17.

Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.

Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, Davis DL, Gailunas AF, Thorsett ED, Sinha S, Knops JE, Jewett NE, Anderson JP, John V.

J Med Chem. 2003 May 8;46(10):1799-802.

PMID:
12723942
18.

A series of C-terminal amino alcohol dipeptide A beta inhibitors.

Garofalo AW, Wone DW, Phuc A, Audia JE, Bales CA, Dovey HF, Dressen DB, Folmer B, Goldbach EG, Guinn AC, Latimer LH, Mabry TE, Nissen JS, Pleiss MA, Sohn S, Thorsett ED, Tung JS, Wu J.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3051-3.

PMID:
12372499
19.

Design of substrate-based inhibitors of human beta-secretase.

Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John V.

J Med Chem. 2002 Jan 17;45(2):259-62.

PMID:
11784130
20.

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.

Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE.

J Neurochem. 2001 Jan;76(1):173-81.

21.

Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile.

Mesner PW Jr, Bible KC, Martins LM, Kottke TJ, Srinivasula SM, Svingen PA, Chilcote TJ, Basi GS, Tung JS, Krajewski S, Reed JC, Alnemri ES, Earnshaw WC, Kaufmann SH.

J Biol Chem. 1999 Aug 6;274(32):22635-45.

22.

The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.

Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM.

J Biol Chem. 1999 Feb 26;274(9):5810-22.

23.

Characterization of recombinant hepatitis B surface antigen using surface plasmon resonance.

Tung JS, Gimenez J, Przysiecki CT, Mark G.

J Pharm Sci. 1998 Jan;87(1):76-80.

PMID:
9452972
24.

Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis.

Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH.

Blood. 1997 Dec 1;90(11):4283-96.

PMID:
9373239
25.

Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.

Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH.

Blood. 1997 Aug 1;90(3):935-43.

PMID:
9242521
26.

Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis.

Martins LM, Kottke T, Mesner PW, Basi GS, Sinha S, Frigon N Jr, Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH.

J Biol Chem. 1997 Mar 14;272(11):7421-30.

28.

Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody.

Lewis CM, Hollis GF, Mark GE 3rd, Tung JS, Ludmerer SW.

Mol Immunol. 1995 Oct;32(14-15):1065-72.

PMID:
8544856
29.

Enhancing the avidity of a human recombinant anti-HIV-1 monoclonal antibody through oligomerization.

Tsai PK, Burke CJ, Irwin JW, Bruner MW, Tung JS, Hollis GF, Mark GE, Kessler JA 2nd, Boots LJ, Conley AJ, et al.

J Pharm Sci. 1995 Jul;84(7):866-70.

PMID:
7562439
30.

A microplate assay for hyaluronidase and hyaluronidase inhibitors.

Tung JS, Mark GE, Hollis GF.

Anal Biochem. 1994 Nov 15;223(1):149-52.

PMID:
7695091
31.

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

Conley AJ, Kessler JA 2nd, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, Emini EA.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3348-52.

32.

Characterization of cloned human endothelin receptors.

Williams DL Jr, Jones KL, Alves K, Chan CP, Hollis GF, Tung JS.

Life Sci. 1993;53(5):407-14.

PMID:
8336519
33.

Correlation of molecular shape with GPIIb-IIIa receptor antagonist activity in RGD peptides.

Tung JS, Jakubowski JA, Heath WF, Utterback BG, Herron DK.

Receptor. 1993 Winter;3(4):343-56.

PMID:
8142908
34.

Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.

Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang SP, Tung JS, Mark GE, et al.

Circulation. 1991 Jul;84(1):244-53.

PMID:
1905593
35.

Expression and characterization of the N-terminal half of antistasin, an anticoagulant protein derived from the leech Haementeria officinalis.

Palladino LO, Tung JS, Dunwiddie C, Alves K, Lenny AB, Przysiecki C, Lehman D, Nutt E, Cuca GC, Law SW, et al.

Protein Expr Purif. 1991 Feb;2(1):37-42.

PMID:
1821771
36.

Further data on the selective expression of Ly-5 isoforms.

Saga Y, Furukawa K, Rogers P, Tung JS, Parker D, Boyse EA.

Immunogenetics. 1990;31(5-6):296-306.

PMID:
2142476
37.

Purification and characterization of human immunodeficiency virus (HIV) core precursor (p55) expressed in Saccharomyces cerevisiae.

Vlasuk GP, Waxman L, Davis LJ, Dixon RA, Schultz LD, Hofmann KJ, Tung JS, Schulman CA, Ellis RW, Bencen GH, et al.

J Biol Chem. 1989 Jul 15;264(20):12106-12.

38.

Cloning and expression of cDNA encoding antistasin, a leech-derived protein having anti-coagulant and anti-metastatic properties.

Han JH, Law SW, Keller PM, Kniskern PJ, Silberklang M, Tung JS, Gasic TB, Gasic GJ, Friedman PA, Ellis RW.

Gene. 1989 Jan 30;75(1):47-57.

PMID:
2470652
39.

Expression of the Q8/9d gene by T cells of the mouse.

Matsuura A, Schloss R, Shen FW, Tung JS, Hunt SW 3rd, Fisher DA, Hood LE, Boyse EA.

Immunogenetics. 1989;30(3):156-61.

PMID:
2789189
40.

Organization of the Ly-5 gene.

Saga Y, Tung JS, Shen FW, Pancoast TC, Boyse EA.

Mol Cell Biol. 1988 Nov;8(11):4889-95.

41.

Structural features of Ly-5 glycoproteins of the mouse and counterparts in other mammals.

Tung JS, Saga Y, Boyse EA.

Immunogenetics. 1988;28(4):271-7.

PMID:
3417340
42.

Alternative use of 5' exons in the specification of Ly-5 isoforms distinguishing hematopoietic cell lineages.

Saga Y, Tung JS, Shen FW, Boyse EA.

Proc Natl Acad Sci U S A. 1987 Aug;84(15):5364-8.

43.

The incongruous Ly-5 phenotype of lpr/lpr and gld/gld T cells.

Tung JS, Saga Y, Boyse EA.

Immunogenetics. 1987;25(2):126-9. No abstract available.

PMID:
3493214
44.

Sequences of Ly-5 cDNA: isoform-related diversity of Ly-5 mRNA.

Saga Y, Tung JS, Shen FW, Boyse EA.

Proc Natl Acad Sci U S A. 1986 Sep;83(18):6940-4. Erratum in: Proc Natl Acad Sci U S A 1987 Apr;84(7):1991.

45.

Unusual association of beta 2-microglobulin with certain class I heavy chains of the murine major histocompatibility complex.

Bushkin Y, Tung JS, Pinter A, Michaelson J, Boyse EA.

Proc Natl Acad Sci U S A. 1986 Jan;83(2):432-6.

46.

Further definition of the Ly-5 system.

Shen FW, Tung JS, Boyse EA.

Immunogenetics. 1986;24(3):146-9.

PMID:
3489673
47.

Antigenic complexity and protein-structural polymorphism in the Lyb-2 system.

Tung JS, Shen FW, LaRegina V, Boyse EA.

Immunogenetics. 1986;23(3):208-10. No abstract available.

PMID:
2420718
48.

Cloning of Ly-5 cDNA.

Shen FW, Saga Y, Litman G, Freeman G, Tung JS, Cantor H, Boyse EA.

Proc Natl Acad Sci U S A. 1985 Nov;82(21):7360-3.

49.

Additional products of the Tla locus of the mouse.

Chorney MJ, Shen FW, Tung JS, Boyse EA.

Proc Natl Acad Sci U S A. 1985 Oct;82(20):7044-7.

50.

Structural characteristics of Tla products.

Chorney MJ, Tung JS, Bushkin Y, Shen FW.

J Exp Med. 1985 Sep 1;162(3):781-9.

Supplemental Content

Support Center